Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorge Cortes

Showing results (401-410 of 713) with videos related to

Pageof 72
Sort By:
Cancer|December 7, 2005
Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemiaDeborah A Thomas, Andreas H Sarris, Jorge Cortes, et al.
Cancer|February 25, 2003
A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndromeJorge Cortes, Hagop Kantarjian, Maher Albitar, et al.
Cancer|March 11, 2003
Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromesApostolia Tsimberidou, Elihu Estey, Jorge Cortes, et al.
British Journal of Haematology|June 20, 2014
SL-401 and SL-501, targeted therapeutics directed at the interleukin-3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemiaOlga Frolova, Juliana Benito, Chris Brooks, et al.
Leukemia Research|July 30, 2013
Modest activity of pomalidomide in patients with myelofibrosis and significant anemiaNaval Daver, Aditi Shastri, Tapan Kadia, et al.
Cancer|October 21, 2010
A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromeElias Jabbour, Hagop Kantarjian, Farhad Ravandi, et al.
American Journal of Hematology|November 20, 2014
Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibodyElias Jabbour, Susan O'Brien, Xuelin Huang, et al.
Cancer|January 20, 2007
Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemiaYasuhiro Oki, Hagop M Kantarjian, Vazganush Gharibyan, et al.
Cancer|February 23, 2007
Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experienceHagop M Kantarjian, Susan O'Brien, Xuelin Huang, et al.
Cancer|May 12, 2006
Activity of alemtuzumab in patients with CD52-positive acute leukemiaRaoul Tibes, Michael J Keating, Alessandra Ferrajoli, et al.
Pageof 72

Showing results (401-410 of 713) with videos related to

Sort By:
Pageof 72
Cancer|December 7, 2005
Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemiaDeborah A Thomas, Andreas H Sarris, Jorge Cortes, et al.
Cancer|February 25, 2003
A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndromeJorge Cortes, Hagop Kantarjian, Maher Albitar, et al.
Cancer|March 11, 2003
Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromesApostolia Tsimberidou, Elihu Estey, Jorge Cortes, et al.
British Journal of Haematology|June 20, 2014
SL-401 and SL-501, targeted therapeutics directed at the interleukin-3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemiaOlga Frolova, Juliana Benito, Chris Brooks, et al.
Leukemia Research|July 30, 2013
Modest activity of pomalidomide in patients with myelofibrosis and significant anemiaNaval Daver, Aditi Shastri, Tapan Kadia, et al.
Cancer|October 21, 2010
A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromeElias Jabbour, Hagop Kantarjian, Farhad Ravandi, et al.
American Journal of Hematology|November 20, 2014
Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibodyElias Jabbour, Susan O'Brien, Xuelin Huang, et al.
Cancer|January 20, 2007
Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemiaYasuhiro Oki, Hagop M Kantarjian, Vazganush Gharibyan, et al.
Cancer|February 23, 2007
Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experienceHagop M Kantarjian, Susan O'Brien, Xuelin Huang, et al.
Cancer|May 12, 2006
Activity of alemtuzumab in patients with CD52-positive acute leukemiaRaoul Tibes, Michael J Keating, Alessandra Ferrajoli, et al.
Pageof 72